Page 72 - Oncology Coder News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Oncology coder. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Oncology Coder Today - Breaking & Trending Today

Camrelizumab plus rivoceranib superior to sorafenib for treatment of unresectable hepatocellular carcinoma

1. Patients in the camrelizumab-rivoceranib group reported significantly greater progression-free survival than the sorafenib group. 2. Treatment-related deaths were comparable among patients in either group. Evidence Rating Level: 1 (Excellent) Study Rundown: Hepatocellular carcinoma comprises a predominant portion of primary liver malignancies. Immunotherapy combined with anti-angiogenic treatment has shown promise in various advanced solid tumors, ....

Rating Level , Unresectable Hepatocellular , Between Jun , Hepatocellular Carcinoma , Hepatocellular Carcinoma Hcc , Liver Cancer , Chronic Disease ,

Breast Cancer Awareness Month event set for local Church

A local church will put on an informative meeting for women who have gone through or who are diagnosed with breast cancer. ....

United States , Cowboy Church , Breast Cancer Awareness Month , Open Range Cowboy Church ,

Adjuvant everolimus does not improve survival for patients with resected renal cell carcinoma

1. Recurrence-free survival was significantly different between the adjuvant everolimus and placebo groups. 2. Grade 3 or higher adverse events were more frequent in the everolimus group with oral mucositis being the most reported within this treatment arm. Evidence Rating Level: 1 (Excellent) Study Rundown: Patients with renal cell carcinoma face a high risk of ....

United States , Rating Level , Advanced Renal Cell , Between Apr , Immune Checkpoint Inhibitors , Kidney Cancer , Metastatic Renal Cell Carcinoma , Renal Cell Carcinoma , Tyrosine Kinase Inhibitor , Chronic Disease ,

Tour de Rhody cycle event sets fundraising record, boosts cancer research

Tour de Rhody got off the ground in 2019, as a fundraiser for the Brown University Oncology Research Program. ....

Thomas Ollila , Brown University Oncology Research Group , Brown University Oncology Research Program , Lifespan Cancer Institute , Brown University Oncology Research , Rhode Island , United States , Blue Cross Shield , Health Medical Pharma , Bluecross Blueshield Of Tennessee , Anatomical Pathology ,

Atezolizumab, Vemurafenib, and Cobimetinib in Melanoma With CNS Metastases

1. Intracranial objective response rate was 42% in the BRAF V600 mutation-positive cohort and 27% in the BRAFV600 wild-type cohort. 2. Treatment-related grade ≥ 3 adverse events occurred in 68% of the BRAF V600 mutation-positive cohort (most common being lipase increased creatine phosphokinase increased) and 53% in the BRAFV600 wild-type cohort (anemia and dermatitis acneiform). ....

Rating Level , Advanced Melanoma , Ici And Tki , Chronic Disease ,